tbuckley/cabot-search huggingface dataset:
How Many Physicians Can We Afford?
Authors: Kevin Grumbach, Philip R. Lee
Journal: JAMA (1991)

We project physician costs for the year 2,000 under several alternative scenarios, using different assumptions about the future supply of physicians and gross income (or expenditures) per physician. The supply of active, posttraining patient-care physicians is projected to increase from a ratio of 144 per 100,000 population in 1986 to 176 per 100,000 in 2,000. Depending on whether expenditures per physician increase at the rate of the consumer price index, the gross national product, or the historical 1982 through 1987 expenditure trends, there will be an additional cost (in constant 1986 dollars) of $21 billion, $30 billion, or $40 billion, respectively, compared with projected physician costs under a scenario of a constant physician-to-population ratio. The disproportionate growth of costs for practice overhead will pose a particular problem for efforts to restrain inflation of expenditures per physician.
Mortality from coronary heart disease in Asian communities in London.
Authors: P. M. McKeigue, M. G. Marmot
Journal: BMJ (1988)

In England and Wales in 1970-2 mortality from coronary heart disease was 20% higher in men and women who had been born in south Asia than in the general population....[In this one-page article the authors examine] the pattern of mortality in different ethnic groups originating from south Asia by using districts of residence to distinguish communities in which one group predominated; five London boroughs were chosen on this basis....[It is found that] mortality from coronary heart disease among Asians in England and Wales has increased by about 25% since 1970-2.  (EXCERPT)
Global overview of LamisilR
Authors: A.Y. FINLAY
Journal: British Journal of Dermatology (1994)

Terbinafine (Lamisil®) is a new antifungal drug which is now available in many countries worldwide. This review seeks to summarize why terbinafine is of interest and how well it reaches its target sites–the stratum corneum and nail plate. The diseases in which it is potentially effective are described and evidence that terbinafine is of value in these diseases is cited. There are very few effective drugs which do not have some potential for producing side-effects and these are discussed.
Blood pressure and catecholamine responses to 'stress' in normotensive and hypertensive subjects
Authors: A. R. Lorimer, P. W. Macfarlane, G. Provan, T. Duffy, T. D. V. Lawrie
Journal: Cardiovascular Research (1971)

A standardized 'stress' was applied to groups of normotensive and hypertensive subjects. Systolic and diastolic blood pressures rose in both groups but were significantly greater in the hypertensive than in the normotensive group. Urinary catecholamines rose with stress to a similar extent in both groups. There was no evidence that patients with sustained hypertension have an increased production of catecholamines either at rest or under 'stress'.
Doctors Help HIV-Positive Haitian Refugees Gain Freedom From US Government Detention Camp
Authors: Andrew A. Skolnick
Journal: JAMA (1993)

AFTER SPENDING up to 20 months behind barbed wire in a squalid detention camp, more than 300 Haitian refugees are now free in the United States, thanks in large part to a group of physicians who spoke out against the US government's incarceration of men, women, and children for "the crime of being infected with the human immunodeficiency virus [HIV]." At various times this year, more than a dozen physicians traveled to Camp Bulkley, the Haitian refugee detention camp at the US Naval Base at Guantanamo Bay, Cuba, to assess the refugees' plight, counsel them, and advocate improved conditions in the camp. The human rights project was headed by Douglas Shenson, MD, MPH, a board member of Doctors of the World, the New York, NY-based international medical relief organization affiliated with Médecins du Monde (<i>JAMA</i>. 1993;269:2481-2484). Among the physicians sent by the group to Guantanamo Bay to bear witness and
Hermes? Apollo? Ningishzida? Dracunculus?... Dracunculus??
Authors: Dennis Martin Smith
Journal: JAMA (1989)

<h3>To the Editor.—</h3> No snakes! Learn your medicine! You have published several letters that have said the symbol of medicine was the caduceus, with two snakes, and then the staff of Aesculapius with one snake... all wrong! If physicians could remember what they learned in medical school, they would not need reminders of the disease dracunculiasis, or guinea worm disease. This disease has a long history in Asia and Africa, where, after the parasites mature in the abdominal cavity (or sometimes other tissues) and mate, the male dies off and the mature gravid female worm, sometimes up to 1 m long, produces a blister, which ruptures, allowing the worm to emerge slowly from the body. It is a time-honored practice to wind the emerging worm around a small stick. This is the representation, using the staff of Aesculapius, that has become the ancient symbol of medicine.
Low-Birth-Weight Infants Show Earlier Onset of IDDM
Authors: Naznin Khan, Jennifer J Couper
Journal: Diabetes Care (1994)

OBJECTIVE Pancreatic β-cell mass increases rapidly during gestation and early infancy. Infants who are small for gestational age, which is a marker for poor intrauterine nutrition, have reduced β-cell mass. We examined whether weight and length in early infancy, and in inference β-cell mass, is related to age at onset of insulindependent diabetes mellitus (IDDM). RESEARCH DESIGN AND METHODS Data from infant records of 232 patients with IDDM, including birth weight, birth length, gestational age, weight at 6 months of age, and feeding history during the first 6 months of life, were analyzed. Maternal recall was not used for data collection. RESULTS Low-birth-weight infants (&amp;lt;2.5 kg) showed a significantly earlier onset of diabetes (4.3 [3.2–6.0] years vs. 9.0 [5.3–11.8] years, median [25–75th percentile]; P &amp;lt; 0.0001). Infants small for gestational age also had earlier onset than those with birth weight above the 10th percentile after correction for gestational age (6.2 [3.6–10.5] vs. 9.2 [5.4–11.8] years; P &amp;lt; 0.0001). Infants with corrected birth weight: length ratio below the 10th percentile had earlier onset, as did infants with corrected 6-months weight below the 10th percentile (4.9 [2.8–6.0] years vs. 8.8 [5.2–11.8] years; P &amp;lt; 0.0001). Infants who were exclusively breast-fed for 6 months showed a slightly later onset of diabetes than those who were bottle- or mixed-fed, independent of weight (9.4 [5.0–11.3] years vs. 8.3 [4.2–11.7] years; P &amp;lt; 0.0001). CONCLUSIONS Weight and growth parameters in utero and early infancy may influence the age at onset of IDDM. β-cell mass is likely to be a significant factor.
Clinical Implantation with the novel D-13 prosthesis for inguinal hernioplasty: A retrospective cohort study
Authors: Peng-Zhi Gao, Ming Li, Ying-Jian Yu, Xiang-Dong Hao, Wu-Zi Li, Ya-Jun Rong, Zhi-Gang Zheng, Ning Meng
Journal: International Journal of Surgery (2015)
Cisplatin and Renal Magnesium Wasting
Authors: CHARLES F. WINKLER
Journal: Annals of Internal Medicine (1979)

Letters1 September 1979Cisplatin and Renal Magnesium WastingCHARLES F. WINKLER, M.D., MERLE M. MAHR, M.D., HARRY DEBANDI, M.D.CHARLES F. WINKLER, M.D.Search for more papers by this author, MERLE M. MAHR, M.D.Search for more papers by this author, HARRY DEBANDI, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-91-3-502_2 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptTo the editor: The efficacy of cisplatin (cis-diamminedichloroplatinum II) in the treatment of solid tumors as well as the side-effects of the agent have been reported. Included in these side-effects are hyperuricemia and hypokalemia (1) Drs. Schilsky and Anderson (2) report an unknown complication of hypomagnesemia and renal magnesium wasting in patients receiving cisplatin in which withdrawal of the cisplatin was associated with normalization of serum magnesemia and absence of renal magnesium wasting. We wish to report an extreme case of hypomagnesemic hypocalcemic tetany with marked hypokalemia secondary to cisplatin in which the drug was continued and electrolyte losses were...References1. ROZENCWEIGVON HOFFSLAVIKMUGGIA MDMF. Cis-diamminedichloroplatinum (II): a new anticancer drug. Ann Intern Med 1977;86:803-12. LinkGoogle Scholar2. SCHILSKYANDERSON RT. Hypomagnesemia and renal magnesium wasting in patients receiving cisplatin. Ann Intern Med. 90:929-31. LinkGoogle Scholar3. RIELLASCRIBNER MB. Five year's experience with a right atrial catheter for prolonged parenteral nutrition at home. Surg Gynecol Obstet. 1979;143:205-8. Google Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAuthors: CHARLES F. WINKLER, M.D.; MERLE M. MAHR, M.D.; HARRY DEBANDI, M.D.Affiliations: Veterans Administration Medical Center Louisville, KY 40202 PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byPreparation of PCL Electrospun Fibers Loaded with Cisplatin and Their Potential Application for the Treatment of Prostate CancerElectrospun Poly(ε-caprolactone) Composite Nanofibers with Controlled Release of Cis-Diamminediiodoplatinum for a Higher Anticancer ActivityCisplatin OverdoseMagnesium Depletion in Patients Receiving Cisplatin-based ChemotherapyDrug-Induced HypomagnesaemiaA randomised study to determine whether routine intravenous magnesium supplements are necessary in patients receiving cisplatin chemotherapy with continuous infusion 5-fluorouracilHypomagnesemia and Renal Magnesium Wasting in Patients Treated With Cisplatincis-Platinum-induced hypomagnesemia and peripheral neuropathy 1 September 1979Volume 91, Issue 3Page: 502-503KeywordsDrugsHypomagnesemiaMagnesium ePublished: 1 December 2008 Issue Published: 1 September 1979 PDF downloadLoading ...
Refugee doctors forced to do menial jobs
Authors: B. Hope
Journal: BMJ (1997)

Illogical and inhumane legislation drives highly motivated refugee professionals into menial jobs and destitution, says a report from the Low Pay Unit and the World University Service. Tough immigration laws, aimed at discouraging “bogus” asylum seekers, leave an estim-ated 74 000 people awaiting confirmation of refugee status, which would …
A multicentre randomized trial of the treatment of patients with pemphigus vulgaris with infliximab and prednisone compared with prednisone alone
Authors: R.P. Hall, J. Fairley, D. Woodley, V.P. Werth, D. Hannah, R.D. Streilein, J. McKillip, J. Okawa, M. Rose, L.L. Keyes-Elstein, A. Pinckney, A. Overington, J. Wedgwood, L. Ding, B. Welch
Journal: British Journal of Dermatology (2014)

Pemphigus vulgaris (PV) is a blistering disease and tumour necrosis factor-α has a role in its pathogenesis.To evaluate the safety of infliximab (IFX) with prednisone compared with prednisone alone in the treatment of PV. In addition, treatment response was assessed and mechanistic studies were performed.Subjects with PV who had ongoing disease activity while being maintained on prednisone were randomized to receive either IFX or placebo in addition to prednisone. Response status and immunoglobulin (Ig) G anti-desmoglein (Dsg)1 and Dsg3 antibodies were assessed at 18 and 26 weeks.Ten subjects were randomized to each group. There were no safety signals during the course of the study. At week 18, one subject in each group had responded. At week 26, three IFX-treated subjects vs. none in the placebo group had responded (P = 0·21). At weeks 18 and 26, the median IgG anti-Dsg1 and anti-Dsg3 levels were lower in the IFX-treated patients [IgG anti-Dsg-1 (week 18, P = 0·035; week 26, P = 0·022); IgG anti-Dsg3 (week 18, P = 0·035; week, 26 P = 0·05)].This study is limited by the relatively small sample size. There was no significant difference between study arms in the proportion of subjects with treatment-related adverse events > grade 3. IFX therapy was not shown to be effective for the treatment of patients with PV in this randomized, placebo-controlled trial, although IFX treatment may be associated with a decrease in anti-Dsg1 and Dsg3 antibodies.
Quality of Life Adds a Human Dimension to Studies on Treatment Cost-Effectiveness
Authors: T. Reynolds
Journal: JNCI Journal of the National Cancer Institute (1994)

Journal Article Quality of Life Adds a Human Dimension to Studies on Treatment Cost-Effectiveness Get access Tom Reynolds Tom Reynolds Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 86, Issue 9, 4 May 1994, Pages 661–662, https://doi.org/10.1093/jnci/86.9.661 Published: 04 May 1994
Direct evidence of a role for mast cells in the pathogenesis of antigen-induced bronchoconstriction.
Authors: T B Casale, D Wood, H B Richerson, B Zehr, D Zavala, G W Hunninghake
Journal: Journal of Clinical Investigation (1987)

We measured bronchoalveolar lavage (BAL) fluid histamine levels in allergic asthmatics and nonallergic normal subjects after local airway antigen and cold 22 degrees C normal saline challenges. Immediately after instillation of antigen through a bronchoscope wedged into a subsegmental airway, all 17 allergic asthmatics but none of the nine normal subjects had visible airway constriction. The asthmatics had a concomitant mean increase in BAL histamine of 23% (P = 0.005), whereas the normals had no change in BAL histamine. Among the allergic asthmatics, the change in BAL histamine content in response to antigen directly correlated with the control (baseline) BAL histamine content (r = 0.66, P = 0.003). Moreover, asthmatics with large antigen-induced changes in BAL histamine had greater airway methacholine sensitivity than did asthmatics without measurable increases in BAL histamine (8 +/- 2 vs. 41 +/- 31 breath units). Neither asthmatics nor normal subjects had airway constriction or changes in BAL histamine levels in response to nonspecific challenge with cold saline. Our data suggest that when allergic asthmatics are exposed to relevant antigens they have in vivo lung mast cell degranulation which results in airway constriction and contributes to nonspecific airway hyperresponsiveness.
P210 Defining the minimal important difference for the visual analogue scale for dyspnoea in patients with malignant pleural effusions
Authors: EK Mishra, J Corcoran, R Hallifax, J Stradling, N Maskell, N Rahman
Journal: Thorax (2013)

<h3>Background</h3> Malignant pleural effusions (MPEs) cause disabling dyspnoea in over 1 million people worldwide per year. Currently recruiting and recently reported randomised controlled trials (RCTs) use the visual analogue scale for dyspnoea (VASD) to assess mean daily breathlessness in patients with MPEs (ISRCTN12852177, ISRCTN4784593, ISRCTN73255764) in order to provide evidence for the optimal method of symptom palliation. The VASD consists of a 100 mm line which subjects mark at a point representing their dyspnoea intensity. Determination of the minimal important difference (MID) for the VASD in patients with MPEs is essential to interpret the results of these trials. <h3>Methods</h3> Patients with a confirmed or suspected MPE undergoing a pleural procedure recorded their baseline VASD prior to the procedure and, 24 hours later, their post-procedure VASD and assessed their dyspnoea on a 7 point Likert scale. Age, gender, diagnosis, procedure performed and volume of fluid drained were also recorded. <h3>Results</h3> A total of 114/123 (93%) questionnaires were returned. Mean age of respondents was 70 years and 56% were female. Commonest malignancies were breast (41%), mesothelioma (26%) and non-small cell lung cancer (18%). Procedures included: therapeutic aspiration (35%), medical thoracoscopy (27%), chest drain insertion (11%), diagnostic tap (11%) and indwelling pleural catheter insertion (8.8%). The mean decrease in VASD in patients reporting a ‘small but just worthwhile decrease’ in their dyspnoea (i.e. equivalent to the MID) was 19mm (95% CI 14–24 mm). The volume of fluid required to drain to produce a change in VASD of 19mm was 760ml. Mean decrease in VASD for the different procedures were: chest drain 41mm; IPC insertion and drainage 41mm; therapeutic aspiration 31mm; diagnostic aspiration 19mm; and LAT 24mm. <h3>Conclusion</h3> The MID for the VASD in patients with a MPE undergoing a pleural procedure is 19mm (95% CI 14–24mm). This value should be used when interpreting the results of RCTs in patients with MPEs using the VASD as an outcome measure and to calculate the sample size for future RCTs.
NASA research fosters rehabilitative device
Authors: Phil Gunby
Journal: JAMA (1981)

More than two years ago, a National Aeronautics and Space Administration (NASA) physician arranged for some Philadelphia researchers visiting NASA's Ames Research Center, Moffett Field, Calif, to see some of the minimum-friction devices used to simulate satellite motion, spacecraft acceleration, and prolonged weightlessness. Out of that visit has come a device that may help some brain-injured children and adults learn or relearn how to crawl. The visitors, from the independent, private Institutes for the Achievement of Human Potential, talked that day with Hubert C. ("Vic") Vykukal, BSME, a NASA research scientist. From this and subsequent conversations evolved the "vehicle for initial crawling," so named because its acronym is the same as its developer's nickname—VIC. The crawling-assistance device is being evaluated for possible roles in rehabilitation efforts. Fifty such devices have been built for the Philadelphia facility by a contractor at a cost of $110 apiece. Essentially, the device consists of
Elastic fiber proteins in the glomerular mesangium in vivo and in cell culture
Authors: R. Bernd Sterzel, Andrea Hartner, Ursula Schlötzer-Schrehardt, Susanne Voit, Birgit Hausknecht, Roberto Doliana, Alfonso Colombatti, Mark A. Gibson, Paola Braghetta, Giorgio M. Bressan
Journal: Kidney International (2000)
Atrial Flutter and Fibrillation: From Basic to Clinical Applications
Authors: John F. Moran
Journal: Annals of Internal Medicine (1998)

Medical Writings15 July 1998Atrial Flutter and Fibrillation: From Basic to Clinical ApplicationsJohn F. Moran, MDJohn F. Moran, MDLoyola University Medical Center, Maywood, IllinoisSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-129-2-199807150-00041 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Atrial Flutter and Fibrillation: From Basic to Clinical Applications; Saoudi N, Schoels W, El-Sherif N; eds. 372 pages. Armonk, NY: Futura; 1998. $85.00. ISBN 0879936614. Order phone 800-877-8761.Field of medicine: Cardiovascular medicine.Format: Hardcover book.Audience: Cardiologists, internal medicine practitioners, residents, and cardiology fellows.Purpose: To provide an up-to-date, state-of-the-art review of atrial fibrillation and flutter from its basic mechanisms to the clinical problems encountered in treating it.Content: This multiauthor text from a distinguished group of investigators attempts to integrate basic and clinical observations in atrial fibrillation and to develop new concepts for dealing with the mechanisms and ... Author, Article, and Disclosure InformationAffiliations: Loyola University Medical Center, Maywood, Illinois PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 15 July 1998Volume 129, Issue 2Page: 168KeywordsArrhythmiaAtrial fibrillationCardiology and cardiovascular diseasesCathetersDrug therapyElectrophysiological techniquesPatientsTachycardia ePublished: 15 August 2000 Issue Published: 15 July 1998 Copyright & PermissionsCopyright © 1998 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
LEFT BUNDLE BRANCH BLOCK IS NOT INDEPENDENTLY ASSOCIATED WITH LONG TERM MORTALITY AMONG PATIENTS WITH PRESERVED LEFT VENTRICULAR EJECTION FRACTION
Authors: Mads K. Ersboll, Zainab Samad, Fawaz Alenezi, Galen Wagner, James Daubert, Joseph Kisslo, Lars Kober, Eric Velazquez
Journal: Journal of the American College of Cardiology (2014)
Comparison of whole-blood eosinophil counts in extrinsic asthmatics with acute and chronic asthma.
Authors: A R Luksza, D K Jones
Journal: BMJ (1982)

Venous whole-blood eosinophil counts were performed on 50 occasions in 42 patients with varying patterns of asthma. None of the patients studied had received systemic corticosteroids during the previous year. Patients with acute severe asthma, as defined by symptomatic airways obstruction with a tachycardia of at least 120 beats/min, showed eosinopenia (21 x 10(9)/l +/- SD 57 x 10(9)/l). Patients with chronic asthma, as defined by symptomatic airways obstruction with a heart rate of less than 100 beats/min, showed appreciable eosinophilia (1048 x 10(9)/l +/- SD 708 x 10(9)/l). Finally, asymptomatic patients had a variable total eosinophil count but with values lower than those of patients with chronic asthma (345 x 10(9)/l +/- SD 431 x 10(9)/l). Eosinophilia may contain chronic asthma, thereby mediating bronchial damage, whereas absence of eosinophils in acute asthma enables vasoactive mediators to enter the systemic circulation, possibly causing circulatory disturbances.
Clinical Neuropharmacology of Hypothalamic Releasing Factors
Authors: Lawrence A. Frohman
Journal: New England Journal of Medicine (1972)

DURING the past decade developments in the area of neuroendocrine research have transformed it into one of the most exciting and rapidly changing aspects of endocrinology. The chemotransmitter concept of neural control of the anterior pituitary gland has been established, several of the hypothalamic releasing factors or releasing hormones have been purified, characterized and even synthesized, and extensive investigation of neuropharmacologic control mechanisms has been performed. Several excellent reviews and symposia have recently appeared.1 2 3 4 5 6 7 This review will attempt to assess the current concepts of the neurochemical basis of hypothalamic releasing-factor control and to summarize at the clinical level the present . . .
Jeanne Daphne Reeve
Authors: Mary Sibellas, Jean Bond
Journal: BMJ (2004)

Consultant haematologist North Middlesex Hospital, London, 1965-92 (b Quetta 1933; q Royal Free Hospital, London, 1957; FRCPath), died from a pulmonary embolus on 22 September 2004.​2004.




Figure 1




Jeanne spent the second world war in Switzerland and spoke French as her first language. Her English always retained a marked accent. She worked at University College Hospital, Ibadan, for two years on a rotating pathology registrar's post and became an expert in sickle cell disease. This knowledge was invaluable on her return to London, where she worked among multiethnic communities at the Royal Free, the Whittington, and the Prince of Wales Hospital. Subsequently the department was merged with the North Middlesex Hospital, where she remained until her retirement. Bridge, golf, and tennis were her great passions.
Compliance of cirrhotic patients with spontaneous bacterial peritonitis to prophylacyic antibiotic therapy
Authors: A.R. Abulfutuh, M.A. Morsy, A.M. Solyman, S.M. El Hendawy, M.E. El Desouky, S.M. El Hadad, M.M. Kamel
Journal: Journal of Hepatology (2003)
Outcome of breech delivery at term.
Authors: I. Z. MacKenzie, M. Jefferies
Journal: BMJ (1992)

carotid stenosis of greater than 70% requiring endarterectomy.Of these 13 patients, 1-66 would have a stroke in the next three years, compared with 2-86 if no operations were performed-an annual saving of 1-2 strokes.Though such treatment is of paramount im- portance to those patients spared a stroke, in relative terms the need for high quality acute care and subsequent rehabilitation remains of prime importance to the 249 other patients who will continue to suffer strokes each year.